Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03000452
Title A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene

multiple myeloma


Daratumumab + Durvalumab

Age Groups: adult | senior
Covered Countries USA | ESP | AUT

No variant requirements are available.